Recent studies of PCa tumorigenesis and progression shed lights on many novel molecular abnormalities which may lead to potential new therapeutic approaches, such as TMPRSS2::ERG gene fusion, loss-of-function mutations of SPOP gene, gain-of-function mutations of FOXA1, amplification of AR (androgen receptor) and MYC, and epigenetic abnormalities such as that mediated by EZH2 (enhancer of zeste homolog 2) deregulation [2]. This evidence concerns the gene EZH2 and posterior cortical atrophy.